Summit Therapeutics Q2 EPS $(0.27) Down From $(0.23) YoY, Sales $57.00K Down From $170.00K YoY
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.27) per share. This is a 17.39 percent decrease over losses of $(0.23) per share from the same period last year. The company reported $57.00 thousand in